Johnson & Johnson vs. Kenvue: Two Healthcare Stocks with Different Fortunes
Johnson & Johnson and Kenvue are two healthcare companies that have piqued the interest of dividend investors. While both names offer a long history of dividend increases, their business models and prospects differ significantly.
Johnson & Johnson has been raising its dividend for over 50 consecutive years and is set to hit its 64th year of annual increases in 2026. The company's forward dividend yield stands at approximately 2%, with a payout ratio of $5.36 per share. However, the company's litigation woes, particularly regarding talc-based baby powder claims, pose a significant risk.
Johnson & Johnson has reserved around $3.7 billion for talc-related liabilities as of Q2 2026. If settlements are reached, this could erode cash that might otherwise be allocated to dividends, research and development, or acquisitions. The stock trades at a P/E ratio of about 31 times, above the industry average of 25 times.
Kenvue, on the other hand, has a more uncertain path ahead as it is currently awaiting its acquisition by Kimberly-Clark in a deal valued at approximately $48.7 billion. Kenvue's business model relies heavily on mature consumer staples brands such as Tylenol and Band-Aid, which have slow growth rates.
Wall Street analysts have a consensus rating of 'Hold' on Kenvue, with an average price target of $19. The acquisition by Kimberly-Clark changes the investment thesis for Kenvue, making it more akin to betting on the success of the combined company's dividend outlook.